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guideline and the shortly coming updated version is an appropriate time to review
and compare it with other European guidelines in order to identify the main sim-
ilarities and differences in key features. METHODS: We chose 14 European guide-
lines and compared them based on the 32 key guideline features developed by
Hjelmgren et al. RESULTS: No relevant differences were found between the Hun-
garian and the European guidelines in tha major part (23) of the key features. The
Hungarian guideline represented nearly the same methodological aspects for ex-
ample in the choice of comparator, time horizon, discount rate and financial im-
pact analysis. We appraised relevant differences in the perspective of the PE stud-
ies, preferred analytical technic (CMA, CEA, CUA, CBA), systematic review of
evidences, costs to be included, preferred outcome measure and deliver utility. The
QALY is the preferred health outcome measure in cost utility studies almost in
every European countries, however only the English and Scottish guidelines re-
quire only EQ-5D profile to deliver utility. In the new version of the Hungarian
guideline the discount rate will be changed from 5% to 3,7%, the cost-effectiveness
threshold will be explicitly determined (twofold and threefold of GDP per capita)
and the direct comparisons will be preferred instead of indirect comparisons.
CONCLUSIONS:Generally we concluded that the Hungarian guideline published in
2002 and also the new modified version basicly require the same approach and
expectations as the European ones. Change in three main things (discount rate,
cost-effectivess threshold, direct comparison preference) makes our guidelines
more elaborated that could help the rational decision-making. The explicitly de-
termined cost-effectiveness threshold requires specification in the method of de-
livering utility in the future.
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OBJECTIVES: Swiss Health Technology Assessment (HTA) initiatives have been
fragmented, and official HTA processes by the Federal Office of Public Health
(Bundesamt fuer Gesundheit, BAG) have been limited to new technologies and
impaired by the absence of a clear-cut separation of assessment and appraisal.
METHODS: Therefore, santésuisse (the national association of sick funds) and In-
terpharma (representing the interests of the Swiss research-based pharmaceutical
industry) initiated “SwissHTA”, a transparent and inclusive project designed to
develop a national consensus how Switzerland might better use HTAs. The process
was led by a project team, with membership from santésuisse (and Helsana), In-
terpharma (and Roche), the Swiss federal government (BAG), the Swiss Medical
Association (FMH), and the Swiss Academy of Medical Sciences (SAMW). After
seven retreats of the project team and three workshops in the course of 12 months,
the team reached a consensus. RESULTS: The Swiss HTA consensus statement
emphasizes the need for a broad technology focus (covering both new and existing
ones by specific approaches following a common set of core principles) and recom-
mends opportunities for stakeholder involvement throughout the HTA processes.
Primary evaluation criteria should be determined by the social preferences of the
Swiss population, constrained by a prior normative commitment in line with con-
stitutional provisions and the principled, rights-based legal tradition of Switzer-
land. The full range of health-related benefits should be evaluated, and assessment
of clinical evidence should take into account the level of evidence that can reason-
ably be expected in a given context, rating the degree of confidence in outcomes in
relation to the relevance and the magnitude of the effects observed. Economic
viability should be evaluated based on budgetary impact and cost benefit ratios,
whereas the consensus rejects the idea of uniform cost per QALY benchmarks.
CONCLUSIONS: The Swiss HTA consensus combines a pragmatic approach with
well-defined evolutionary options.
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OBJECTIVES: HTA has the increasing role in decision-making process in new EU
member states. Health care systems miscellaneousness causes differences in HTA
exploitation and its characteristics. Our objective was to make an overview of HTA
within these countries to show similarities and its differences. METHODS: Litera-
ture search was done on governmental and governmental like sites to find HTA
related Acts, regulation, guidelines or other relevant documents which describes
HTA country specific approach in new EU member states. First search was relevant
to presence of HTA. In those of them where HTA is defined in legislation we com-
pared several characteristics: model, role, type of HTA, role of pharmacoeconomic,
threshold, discounting factor, sensitivity analysis and differentiation of ap-
proaches between therapeutic and prophylactic approaches. RESULTS: Out of 12
new EU member states (accessed in May 2004 or later) 10 applies HTA, 8 as light
version, 2 as robust NICE like version. HTA has impactful position in 5 of them
(Poland, Slovenia, Slovakia, Estonia and Latvia). Only Poland applies full HTA ap-
proach. Rest of countries use narrow pharmacoeconomic approach. Threshold is
officially published in primary legislation in 2 countries (Poland, Slovakia). Dis-
counting factor varies between 3% and 5%. There was no difference recognized in
evaluation of either therapeutic or prophylactic approaches. CONCLUSIONS: HTA
form and role differ in new EU member states, but some similarities were identi-
fied. These similarities cannot presume any transferability of HTA decision, as it
depends on the other factors like health care system, composition of costs and
methods of its reimbursement by different bodies within relevant country. But
certain common areas for cooperation could be established based on that.
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OBJECTIVES: Patient registries are an important tool for many types of clinical
research, including studies of comparative effectiveness, cost effectiveness, treat-
ment patterns, patient outcomes, and natural history of disease. Use of registries is
increasing, but there is no central database in the U.S. designed specifically to list
patient registries. A searchable public database that is designed to provide infor-
mation about patient registries would support research collaborations, reduce re-
dundancies, encourage the efficient use of resources, and improve transparency in
observational clinical research. The goal of this project, funded by the Agency for
Healthcare Research and Quality, is to design and develop a Registry of Patient
Registries (RoPR) system that meets the needs of a diverse set of stakeholders.
METHODS: Stakeholders from a broad range of organizations and with varying
levels of familiarity with patient registries were identified and invited to participate
in a series of remote and in-person meetings to gather and refine the RoPR system
requirements. Requirements were also revised through public comment and us-
ability and pilot testing. Over 320 individuals participated in RoPR design activities.
RESULTS: Stakeholders identified a range of challenges facing the RoPR system.
Challenges include improving understanding of the distinction between observa-
tional studies, patient registries, and other types of clinical research; determining
how to provide useful information to assess registry quality; ensuring that registry
listings are sufficiently complete; and motivating registry sponsors to list their
registries in a voluntary system. CONCLUSIONS: In response to stakeholder feed-
back, the RoPR was designed as an integrated system with ClinicalTrials.gov that
collects information on registry purpose, classification, objectives, data collected,
progress reports, and interest in collaboration and data sharing. Some challenges
identified through stakeholder discussions were addressed in the system design.
Other challenges must be addressed through education and collection of stake-
holder feedback following the RoPR launch in September 2012.
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OBJECTIVES: Disability is a global public health priority strongly related to socio-
economic status (SES). Social capital (SC) is a complex construct and little is known
about how it relates to SES and disability in a middle-income country. This study’s
purpose was to explore this relationship in Chile. METHODS: Cross-sectional anal-
ysis of Chilean National Health Survey-2010 (n5037). Health outcome: Composite
index of disability (continuous variable, range 0-100). Dependent variables: a) SES
measures: household income per capita (tertiles), educational level (primary/sec-
ondary/higher), employment status (yes/no), and household assets index (tertiles).
b) SC dimensions: interpersonal trust (3 variables), financial/emotional support (2
variables) and social participation (2 variables). After factor analysis, s 2 factors
explained 60% variance (low uniqueness in all variables), with exception of social
participation which was assess separately. After orthogonal-varimax-rotation, 2
continuous aggregated variables were considered for analysis: trust and social sup-
port. Kaiser-Meyer-Olkin0.62; Cronbach alpha0.64 and 0.78 for trust and social
support, respectively. c) Demographic factors: age, sex, marital status, rural/urban
Weighted multiple linear regression models analyzed in R. Confounding and mul-
tiple interactions terms were explored. RESULTS: Mean of disability was 18.8pts. A
significant crude association between disability and SES was observed. All dimen-
sions of SC were significantly associated with disability (Trust: 7.6pts, Support:
10.7pts, Participation:2.0pts). Adjusted regressions showed SES reduced the
magnitude of its association to disability by 70% when dimensions of SC were
added to the model, but remained significant. Social participation lost statistical
significance in presence of SES. Multiplicative interaction terms were found be-
tween SC and education, providing additional higher chance to be disabled when
being poorly educated and having low trust and support. CONCLUSIONS: There is
a complex relationship between disability, SES and SC. Interactions between SES
and SC significantly modify the chance of being disabled and this needs further
consideration in the context of a middle-income country.
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